John Woytowicz, MD
Family Medicine · Auburn, MENPI 1205802212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,596 and has fallen 70.5% since, to $470 in 2025. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$536
- AstraZeneca$396
- AbbVie$315
- Exact Sciences$234
- Pfizer$211
- Novo Nordisk$177
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,923100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $536 |
| AstraZeneca | 22 | $396 |
| AbbVie | 15 | $315 |
| Exact Sciences | 10 | $234 |
| Pfizer | 11 | $211 |
| Novo Nordisk | 10 | $177 |
| Teva Pharmaceuticals USA, Inc. | 10 | $165 |
| GSK | 9 | $163 |
| Merck | 7 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Boehringer Ingelheim | 5 | $89 |
| Astellas Pharma US Inc | 5 | $88 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Lilly USA, LLC | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Dexcom, Inc. | 1 | $39 |
| Boston Scientific | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Circassia Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $15 |
How this compares
$2,923 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $45,331 |
| TrulicityDulaglutide | 22 | $35,803 |
| FarxigaDapagliflozin Propanediol | 24 | $29,103 |
| OzempicSemaglutide | 24 | $25,045 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,977 |
| JardianceEmpagliflozin | 25 | $19,382 |
| JanuviaSitagliptin Phosphate | 19 | $17,322 |
| MyrbetriqMirabegron | 11 | $10,225 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $7,820 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,692 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 198 | $6,978 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,632 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $6,269 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $6,054 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $4,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $211 | $45,33141 claims |
| Lilly USA, LLCTrulicity | $60 | $35,80322 claims |
| AstraZenecaFarxiga, Symbicort | $396 | $35,73547 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $89 | $27,07441 claims |
| Novo NordiskOzempic | $177 | $25,04524 claims |
| GSKTrelegy Ellipta | $163 | $23,97734 claims |
| MerckJanuvia | $119 | $17,32219 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $10,22511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Auburn
- Mohamed Gamal-EldinAuburn$2K
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.